FLOSEAL
The Next Generation: FLOSEAL with RECOTHROM
Unmatched speed. Reliable hemostasis.
The FIRST AND ONLY active flowable hemostat kitted with recombinant thrombin2
Faster Preparation — More than 1.5x faster prep time compared to Surgiflo2
Easy Preparation — Compared to Surgiflo, FLOSEAL with RECOTHROM was rated easier to prepare with less steps2
Most preferred product configuration (compared to FLOSEAL with human thrombin and Surgiflo)2
RECOTHROM is manufactured in the laboratory setting using recombinant DNA technology to provide the following benefits:1
- No human blood components1
- Structurally similar to naturally occurring human thrombin1
- Eliminates reliance on human blood donations to source thrombin1
Choose Better Outcomes. Choose FLOSEAL.
Inadequate surgical hemostasis and uncontrolled bleeding may lead to transfusion and/or other bleeding-related complications,3 lower clinical outcomes and higher hospital costs.4
For the last 20+ years, FLOSEAL Hemostatic Matrix has been shown to result in better clinical and hospital resource utilization outcomes.5
Additional Product Benefits
The Leader in Hemostasis
For certain surgical procedures, use of FLOSEAL Hemostatic Matrix is associated with shorter length of surgery,6 fewer intensive care unit days,7 significantly lower risks of minor complications, blood transfusions and surgical revisions.6
Consistent Performance
FLOSEAL has been proven to perform fast and consistently across a range of bleeds.8*
*Based on pre-clinical data.
Health Economic Benefits
The use of FLOSEAL can result in improved Resource Utilization Outcomes and substantial Cost Savings for hospitals – up to $1.5M per year for a hospital performing 245 mixed cardiac surgical procedures per year9 and $2,445 per spine procedure.10